RxDoctor Payments Data

Steven Newhall, PA

Medical · Medford, ORNPI 1023404035

Payments from drug & device makers

$497in general payments, 2019–2025

Across 20 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$131
  • Sanofi-aventis U.S. LLC$91
  • Novo Nordisk$67
  • Tandem Diabetes Care, Inc.$43
  • Medtronic$42
  • BETA Bionics, Inc.$38
  • plus $86 from 4 others

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$497 in reported general payments places this provider in the 60th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon

Medicare billing

Part B allowed, 2024
$63,403
Medicare patients
280
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide224$292,056
MounjaroTirzepatide211$248,002
JardianceEmpagliflozin166$193,259
TrulicityDulaglutide94$114,295
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$59,766
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog96$56,662
Fiasp FlextouchInsulin Aspart (Niacinamide)39$52,076
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$51,227
Semglee (Yfgn) PenInsulin Glargine-Yfgn78$48,999
Tresiba Flextouch U-100Insulin Degludec44$40,231
Lantus SolostarInsulin Glargine,hum.Rec.Anlog169$29,131
RybelsusSemaglutide19$27,435
Novolog FlexpenInsulin Aspart62$26,826
Soliqua 100-33Insulin Glargine/Lixisenatide23$25,261
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$23,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog, Insulin Lispro$17$379,984370 claims
Novo NordiskOzempic, Rybelsus, Novolog$67$328,846265 claims
Boehringer IngelheimJardiance$22$193,259166 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$91$30,13138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 364 medical providers in Oregon.

Other medical in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →